Geneva, April 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600121799) titled 'To develop a model to predict complete response and relapse in patients with bullous pemphigoid receiving dupilumab' on April 3.
Study Type: Observational study
Study Design:
Sequential
Primary Sponsor: Peking University First Hospital
Condition:
bullous pemphigoid
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-02-01
Target Sample Size: Recurrence group and non-recurrence group:278;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=312740
Published by HT Digital Content Services with permission from Health Daily Digest....